This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (133)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic

The ISAR-REACT 2 Randomized Trial

Adnan Kastrati, MD; Julinda Mehilli, MD; Franz-Josef Neumann, MD; Franz Dotzer, MD; Jurriën ten Berg, MD; Hildegard Bollwein, MD; Isolde Graf, PharmD; Maryam Ibrahim, MD; Jürgen Pache, MD; Melchior Seyfarth, MD; Helmut Schühlen, MD; Josef Dirschinger, MD; Peter B. Berger, MD; Albert Schömig, MD; for the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators

JAMA. 2006;295:1531-1538. Published online March 13, 2006 (doi:10.1001/jama.295.13.joc60034).

Context  No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients with non–ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg of clopidogrel.

Objective  To assess whether abciximab is associated with clinical benefit in high-risk patients with ACS undergoing PCI after pretreatment with 600 mg of clopidogrel.

Design, Setting, and Patients  International, multicenter, randomized, double-blind, placebo-controlled study conducted from March 2003 through December 2005, enrolling 2022 patients (mean age, 66 years) with non–ST-segment elevation ACS undergoing PCI.

Interventions  Patients were assigned to receive either abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125-µg/kg per minute [maximum, 10 µg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight) or placebo (placebo bolus and infusion of 12 hours, plus heparin bolus, 140 U/kg). All patients received clopidogrel, 600 mg, at least 2 hours prior to the procedure, as well as 500 mg of oral or intravenous aspirin.

Main Outcome Measures  The primary end point was a composite of death, myocardial infarction, or urgent target vessel revascularization occurring within 30 days after randomization; secondary end points were rates of in-hospital major and minor bleeding.

Results  Of 2022 patients enrolled, 1012 were assigned to abciximab and 1010 to placebo. The primary end point was reached in 90 patients (8.9%) assigned to abciximab vs 120 patients (11.9%) assigned to placebo, a 25% reduction in risk with abciximab (relative risk [RR], 0.75; 95% CI, 0.58-0.97; P = .03). Among patients without an elevated troponin level, there was no difference in the incidence of primary end point events between the abciximab group (23/499 patients [4.6%]) and the placebo group (22/474 patients [4.6%]) (RR, 0.99; 95% CI, 0.56-1.76; P = .98), whereas among patients with an elevated troponin level, the incidence of events was significantly lower in the abciximab group (67/513 patients [13.1%]) compared with the placebo group (98/536 patients [18.3%]), which corresponds to an RR of 0.71 (95% CI, 0.54-0.95; P = .02) (P = .07 for interaction). There were no significant differences between the 2 groups regarding the risk of major and minor bleeding as well as need for transfusion.

Conclusions  Abciximab reduces the risk of adverse events in patients with non–ST-segment elevation ACS undergoing PCI after pretreatment with 600 mg of clopidogrel. The benefits provided by abciximab appear to be confined to patients presenting with an elevated troponin level.

Trial Registration  ClinicalTrials.gov Identifier: NCT00133003

Author Affiliations: Deutsches Herzzentrum (Drs Kastrati, Mehilli, Graf, Ibrahim, Pache, Schühlen, and Schömig) and First Medizinische Klinik rechts der Isar (Drs Bollwein, Seyfarth, Dirschinger, and Schömig), Technische Universität, Munich, Germany; Herz-Zentrum, Bad Krozingen, Germany (Dr Neumann); Klinikum Garmisch-Partenkirchen, Germany (Dr Dotzer); St Antonius Ziekenhuis, Nieuwegein, the Netherlands (Dr ten Berg); and Duke Clinical Research Institute, Durham, NC (Dr Berger).

RELATED ARTICLE

Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
Steven R. Steinhubl and Richard Charnigo
JAMA. 2006;295(13):1581-1582.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
Patti et al.
J Am Coll Cardiol 2008;52:1128-1133.
ABSTRACT | FULL TEXT  

What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Williams and Abbott
Circulation 2008;118:1219-1222.
FULL TEXT  

Defining a Role for Novel Biomarkers in Acute Coronary Syndromes
Bonaca and Morrow
Clin. Chem. 2008;54:1424-1431.
ABSTRACT | FULL TEXT  

Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
Kastrati et al.
NEJM 2008;359:688-696.
ABSTRACT | FULL TEXT  

Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry
Jeremias et al.
Circulation 2008;118:632-638.
ABSTRACT | FULL TEXT  

Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome
Dobesh et al.
Am J Health Syst Pharm 2008;65:S22-S28.
ABSTRACT | FULL TEXT  

2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies
Coons and Battistone
The Annals of Pharmacotherapy 2008;42:989-1001.
ABSTRACT | FULL TEXT  

Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8
Widimsky et al.
Eur Heart J 2008;29:1495-1503.
ABSTRACT | FULL TEXT  

Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
Geisler et al.
Heart 2008;94:743-747.
ABSTRACT | FULL TEXT  

Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Patrono et al.
Chest 2008;133:199S-233S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Harrington et al.
Chest 2008;133:670S-707S.
ABSTRACT | FULL TEXT  

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis
Antman et al.
J Am Coll Cardiol 2008;51:2028-2033.
ABSTRACT | FULL TEXT  

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
Kereiakes and Gurbel
J Am Coll Cardiol Intv 2008;1:111-121.
ABSTRACT | FULL TEXT  

N-Terminal B-Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients With Acute Coronary Syndromes and Normal Troponin T Values Upon Admission
Weber et al.
J Am Coll Cardiol 2008;51:1188-1195.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy for Vascular Interventions
Comerota and Thakur
PERSPECT VASC SURG ENDOVASC THER 2008;20:28-35.
ABSTRACT  

Platelets: Inflammatory Firebugs of Vascular Walls
May et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:s5-s10.
ABSTRACT | FULL TEXT  

Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point.
Ndrepepa et al.
J Am Coll Cardiol 2008;51:690-697.
ABSTRACT | FULL TEXT  

Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
Roffi and Mukherjee
Eur Heart J 2008;29:429-431.
FULL TEXT  

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
Ndrepepa et al.
Eur Heart J 2008;29:455-461.
ABSTRACT | FULL TEXT  

Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes have cardiovascular physicians been given enough grace in getting it right?
Gershlick
Heart 2008;94:135-137.
FULL TEXT  

Antiplatelet therapy in acute coronary syndromes
Gitt and Betriu
Eur Heart J Suppl 2008;10:A4-A12.
ABSTRACT | FULL TEXT  

Antiplatelet therapy in percutaneous coronary intervention
Bode and Huber
Eur Heart J Suppl 2008;10:A13-A20.
ABSTRACT | FULL TEXT  

Variability of response to antiplatelet therapy
Storey
Eur Heart J Suppl 2008;10:A21-A27.
ABSTRACT | FULL TEXT  

Platelet Activation in Coronary Artery Disease: Intracardiac vs Peripheral Venous Levels and the Effects of Angioplasty
Jaumdally et al.
Chest 2007;132:1532-1539.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT  

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
von Beckerath et al.
Eur Heart J 2007;28:1814-1819.
ABSTRACT | FULL TEXT  

Dual antiplatelet therapy in high-risk patients
Van de Werf
Eur Heart J Suppl 2007;9:D3-D9.
ABSTRACT | FULL TEXT  

The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2007;50:270-285.
FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

Acute coronary syndromes without ST segment elevation
Peters et al.
BMJ 2007;334:1265-1269.
FULL TEXT  

Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin
Birnbaum et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2891-H2897.
ABSTRACT | FULL TEXT  

Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease
Eshaghian et al.
ANN INTERN MED 2007;146:434-441.
ABSTRACT | FULL TEXT  

Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma
Serebruany
Eur Heart J 2007;28:640-641.
FULL TEXT  

Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial
Stone et al.
JAMA 2007;297:591-602.
ABSTRACT | FULL TEXT  

Variability in response to clopidogrel: where is the threshold for 'low response'?: reply
Geisler and Gawaz
Eur Heart J 2007;0:ehl500v1-1.
FULL TEXT  

Antiplatelet treatment for coronary heart disease
Clappers et al.
Heart 2007;93:258-265.
FULL TEXT  

New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective
Neumann et al.
Eur Heart J Suppl 2007;9:A4-A10.
ABSTRACT | FULL TEXT  

Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
Dudek et al.
Eur Heart J Suppl 2007;9:A25-A31.
ABSTRACT | FULL TEXT  

Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients
Antoniucci
Eur Heart J Suppl 2007;9:A32-A36.
ABSTRACT | FULL TEXT  

Drive-Through Angioplasty: Is It Safe or Necessary?
Mixon and Dehmer
Circulation 2006;114:2578-2580.
FULL TEXT  

A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation
Bertrand et al.
Circulation 2006;114:2636-2643.
ABSTRACT | FULL TEXT  

Bivalirudin for Patients with Acute Coronary Syndromes.
Stone et al.
NEJM 2006;355:2203-2216.
ABSTRACT | FULL TEXT  

Accounting for ACUITY.
Bittl
NEJM 2006;355:2249-2250.
FULL TEXT  

Platelet Function Assessment to Predict Outcomes After Coronary Interventions: Hype or Hope?
Alfonso and Angiolillo
J Am Coll Cardiol 2006;48:1751-1754.
FULL TEXT  

Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
Hochholzer et al.
J Am Coll Cardiol 2006;48:1742-1750.
ABSTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Inhibitors in the Elderly: Fear of Age or Age of Fear?
Montalescot
Circulation 2006;114:2004-2006.
FULL TEXT  

Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions
Ndrepepa et al.
Circulation 2006;114:2040-2046.
ABSTRACT | FULL TEXT  

Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting
Cuisset et al.
J Am Coll Cardiol 2006;48:1339-1345.
ABSTRACT | FULL TEXT  

Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention
Hamdalla and Steinhubl
Eur Heart J Suppl 2006;8:G20-G24.
ABSTRACT | FULL TEXT  

Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes
Bertrand and Van Belle
Eur Heart J Suppl 2006;8:G59-G63.
ABSTRACT | FULL TEXT  

Clinical Guidelines and Practice: In Search of the Truth
Kereiakes and Antman
J Am Coll Cardiol 2006;48:1129-1135.
ABSTRACT | FULL TEXT  

Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2006;11:126-126.
FULL TEXT  

Sophia
Emerg. Med. J. 2006;23:664-664.
FULL TEXT  

The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
Giugliano and Braunwald
J Am Coll Cardiol 2006;48:386-395.
FULL TEXT  

JournalScan
Malik
Heart 2006;92:1007-1008.
FULL TEXT  

JournalScan
Malik
Heart 2006;92:862-864.
FULL TEXT  

Abciximab Before PCI Benefits Patients with NSTE ACS
JWatch Emergency Med. 2006;2006:1-1.
FULL TEXT  

Pre-PCI Abciximab plus Clopidogrel in High-Risk NSTEACS
Journal Watch Cardiology 2006;2006:2-2.
FULL TEXT  

Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
Steinhubl and Charnigo
JAMA 2006;295:1581-1582.
FULL TEXT